Literature DB >> 11202211

New paradigms for growth hormone treatment in the 21st century: prediction models.

M B Ranke1.   

Abstract

Inconsistent and sometimes disappointing final height outcomes in studies in which exogenous growth hormone (GH) was given to children with short stature resulting from various causes have led to attempts to determine the factors that influence responsiveness to GH. Many such factors have been identified, including the genetically determined height potential of the child, the height deficit, current and perinatal auxological and biological factors, and, importantly, GH treatment modalities. These factors vary depending on the cause of the growth failure and during the course of childhood and treatment with GH. Data from well-defined large cohorts can be entered into multiple regression analyses to derive algorithms describing the variation in growth response during a defined period and the influence on this of various factors. Pharmacoepidemiologic surveys have been particularly useful in this regard. Algorithms with low-error SD values, which have included the dose of GH as a variable, can be used to predict the response to a putative GH dose in a similar cohort or in an individual over an equivalent period. A sequential series of such algorithms can be integrated to form a predictive model. Such a model can be used for planning a course of treatment, but the patient data required for entry into the model should be easily obtainable if the model is to have widespread utility. The development of such models will allow GH treatment to be better individualized and optimized for growth and cost outcomes. Growth prediction models will facilitate realistic expectations and will permit stepwise goals to be set and monitored.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11202211     DOI: 10.1515/jpem-2000-s609

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  3 in total

1.  Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®.

Authors:  Peter A Lee; John Germak; Robert Gut; Naum Khutoryansky; Judith Ross
Journal:  Int J Pediatr Endocrinol       Date:  2011-07-07

2.  Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS).

Authors:  Paul B Kaplowitz; Dorothy I Shulman; James W Frane; Joan Jacobs; Barbara Lippe
Journal:  Int J Pediatr Endocrinol       Date:  2013-05-01

3.  Pre-treatment growth and IGF-I deficiency as main predictors of response to growth hormone therapy in neural models.

Authors:  Urszula Smyczyńska; Joanna Smyczyńska; Maciej Hilczer; Renata Stawerska; Ryszard Tadeusiewicz; Andrzej Lewiński
Journal:  Endocr Connect       Date:  2017-12-14       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.